Daniel Ackerman
Research Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
Year:
2025
Introduction: Despite improvements in locoregional therapy, recurrence of hepatocellular carcinoma (HCC) remains common, as tumor cells can respond to therapy by undergoing metabolic reprogramming to utilize anaerobic glycolytic pathways via lactate dehydrogenase. In this work, we assessed the growth rates and recurrence rates of HCC in target tumors undergoing transarterial embolization (TAE) with an LDH inhibitor (LDHi), bland TAE (BLAND), and sham therapy (SHAM). Methods and Materials: Development of autochthonous HCC was induced in 25 Wistar rats using DEN and tumor progressions were tracked with serial MRI until the target tumor reached a volume of 100-300 mm3. TAE with LDHi were performed using sequential administration of 10 µg/kg LDHi followed by 40-120 µm Embosphere (Merit Medical Systems) (n=13), while bland TAE were performed using Embosphere alone(n=8). An additional cohort underwent a sham TAE procedure without the administration of Embosphere (n=4). Following surgery, rats were serially imaged using T2 MRI, where tumor growth was tracked and monitored for treatment response and potential recurrence. Rats were classified as progressive disease (PD) if there was no decrease in tumor volume by <20%, PR if tumor volume decreased by >20%, and CR if the tumor was eradicated. Recurrence following PR was classified by a >20% increase in tumor volume from the lowest post-treatment volume. Results: LDHi target tumors had an average %change in tumor volume of -64% from treatment volume, while the BLAND showed a -38% decrease (p=0.068). Results of a Kaplan-Meier survival analysis with a log-rank test showed a significant difference in survival between the groups (p=0.006). All SHAM rats showed no response to treatment and were classified as PD. Treatment responses in the BLAND cohort were2/8 PD and 6/8 PR, while responses in the LDHi cohort were 1/13 PD, 11/13 PR, and1/13 CR. All rats classified as PR experienced recurrence and the time of progression free survival was significantly longer in the LDHi cohort (24 days) as compared to the BLAND (13 days) (p = 0.036). Conclusion: Administration of LDHi during TAE yields a larger decrease in targeted tumor volume as compared to BLAND TAE, while also providing a statistically significant improvement in progression free survival. Citation Format: Ryan Baron, Ariful Islam, George McClung, Ryan El Ghazal, Nicholas Perkons, Alexey Gurevich, Jennifer Crainic, Daniel Ackerman, Nicolas Skuli, Gregory Nadolski, Stephen Hunt, Terence Gade. Targeted administration of lactate dehydrogenase inhibitor during transarterial of hepatocellular cardinomas in a rat model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6852.
Year:
2025
Background and aims Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies to identify genomic alterations that could lead to actionable drug targets and biomarkers. Methods Optical genome mapping (OGM) and whole exome sequencing (WES) were performed on 70 liver metastases of neuroendocrine tumors from multiple anatomical primary sites. PacBio Iso-Seq long read sequencing and western blotting was used to confirm fusion gene expression. Findings were validated by rtPCR and western blotting on a separate cohort of 17 resection specimens from 14 pancreatic NET cases. Results Somatic variant calling from OGM data detected recurrent fusions involving TBL1X ( PSIP1::TBL1X ) and BEND2 ( CHD7::BEND2 and NEO1::BEND2 ) in pancreatic neuroendocrine tumors (pNETs). BEND2 fusions were associated with high grade tumors, as previously described. The novel PSIP1::TBL1X fusion was confirmed to result in fusion transcript expression by both long-read sequencing and nested rtPCR. Presence of the PSIP1::TBL1X fusion transcript was also confirmed in a second cohort of pNET resection specimens and fusion protein expression was established by western blotting. Both TBL1X and BEND2 fusions are mutually exclusive with ATRX/DAXX mutations. Conclusion This study underscores the importance of structural variants, including fusion genes as both prognostic biomarkers and potential therapeutic targets, especially in ATRX/DAXX negative pNETs. BEND2 fusion positivity may be a clinically useful biomarker for aggressive disease. As all TBL1X fusion isoforms contain the entire TBL1X coding sequence, TBL1X inhibition could be explored as a novel treatment for TBL1X fusion positive pNETs.
Year:
2025
Mass Spectrometry Imaging (MSI) is an emergent tool for analyzing spatial molecular distributions, yet data complexity often hinders effective analysis. MSI.EAGLE, an open-source R-Shiny application, makes analysis accessible for non-specialists by integrating advanced tools in a user-friendly interface. The workflow leverages tools from the Cardinal MSI package, with enhanced phenotyping, segmentation, statistical analysis and visualization. The application addresses a gap in spatial biology research by empowering a broader scientific community.
Year:
2025
Year:
2021
Year:
2020
Collaborators (5)
Garret A. FitzGerald
University of Pennsylvania
Kelley Weinfurtner
Assistant Professor
University of Pennsylvania
Terence Gade
PI
University of Pennsylvania
Bryson Katona
Assistant Professor, Clinician-Educator
University of Pennsylvania
George McClung
Staff Scientist
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.